In the last trading session, 2.47 million shares of the Syros Pharmaceuticals Inc. (NASDAQ:SYRS) were traded, and its beta was 1.58. Most recently the company’s share price was $1.95, and it changed around $0.38 or 24.20% from the last close, which brings the market valuation of the company to $52.12M. SYRS currently trades at a discount to its 52-week high of $8.17, offering almost -318.97% off that amount. The share price’s 52-week low was $1.43, which indicates that the current value has risen by an impressive 26.67% since then. We note from Syros Pharmaceuticals Inc.’s average daily trading volume that its 10-day average is 0.41 million shares, with the 3-month average coming to 253.51K.

Syros Pharmaceuticals Inc. stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 2 recommended SYRS as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight. Syros Pharmaceuticals Inc. is expected to report earnings per share of -0.72 for the current quarter.

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) trade information

Instantly SYRS has showed a green trend with a performance of 24.20% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 2.1296 on recent trading dayincreased the stock’s daily price by 8.43%. The company’s shares are currently down -74.97% year-to-date, but still up 28.71% over the last five days. On the other hand, Syros Pharmaceuticals Inc. (NASDAQ:SYRS) is 20.74% up in the 30-day period. We can see from the shorts that 0.96 million shares have been sold at a short interest cover period of 1.96 day(s).

The consensus price target as assigned by Wall Street analysts is $15, which translates to bulls needing to increase their stock price by 87.0% from its current value. Analyst projections state that SYRS is forecast to be at a low of $13 and a high of $30.

Syros Pharmaceuticals Inc. (SYRS) estimates and forecasts

Syros Pharmaceuticals Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -67.66 percent over the past six months and at a 55.74% annual growth rate that is well above the industry average of 17.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 49.70% in revenue this quarter, and will report an increase of 66.10% in the next quarter. The year-over-year growth rate is expected to be -91.20%, down from the previous year.

Consensus estimates provided by 4 financial analysts predict the company will bring in an average of 450k in revenue for the current quarter. 4 analysts expect Syros Pharmaceuticals Inc. to make 450k in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 3.76M and 387k respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -88.00%. Forecasts for the next quarter put sales growth at 16.30%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.16%.

SYRS Dividends

Syros Pharmaceuticals Inc.’s next quarterly earnings report is expected to be released in October.

Syros Pharmaceuticals Inc. (NASDAQ:SYRS)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.32% of Syros Pharmaceuticals Inc. shares, and 81.10% of them are in the hands of institutional investors. The stock currently has a share float of 82.19%.